Tests a blood marker to predict response to bevacizumab in recurrent glioblastoma
Checks blood levels of soluble CD146 in adults with returning glioblastoma treated with bevacizumab.
Key facts
- Who runs it
- Assistance Publique Hopitaux De Marseille
- Where
- Marseille, FranceSee the site
- Trial code
- Registry title
- Predictive Value of Soluble CD146 in Glioblastoma Patients
- Status
- Recruiting
- People taking part
- 55 people, planned
- Started
- 30 Jan 2024
- Expected to end
- Dec 2026
- Type of study
- Interventional
- Treatments tested
- plasma collection
- Record updated
- 2 February 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose IDH wild-type glioblastoma has come back after standard first treatment and who are going to get bevacizumab. Blood samples are collected to measure soluble CD146.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Recurrent glioblastoma (IDH wild-type) that came back after standard first-line radio-chemotherapy.
- Earlier treatment
- Must have had standard first-line radio-chemotherapy. Must not have had bevacizumab as first-line treatment.
- Biomarker or test result
- IDH wild-type tumor (IDHwt).
Main reasons for not taking part
- Pregnancy or breast feeding
- Life expectancy less than 3 months
- Bevacizumab as first-line treatment
- Another life-threatening disease at the same time
- Under legal protection
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- - Adult patients with recurrent IDHwt glioblastoma
- Relapse after standard first line treatment (radio-chemotherapy)
- Candidate for bevacizumab treatment
- Able to be monitored by MRI
- KPS ≥ 60%
- Written signed consent form
Who cannot take part
- Bevacizumab in first line treatment
- Other concomitant life-threatening disease
- Pregnancy or breast feeding
- Life expectancy less than 3 months
- Under legal protection
Where in France
- Service de Neuro-oncologieMarseille, FranceContact: TABOURET EmelineTaking people
About the trial
What the trial wants to find out
Glioblastoma is the most common malignant primary brain tumor with poor prognosis because of its diffusive and infiltrative nature. The FDA approved the use of the anti-VEGF antibody bevacizumab in recurrent GBM. However, resistance to this anti-angiogenic reagent is frequent and fails to enhance patients' overall survival. The investigators previously identified one novel mechanism responsible for bevacizumab-resistance in CD146-positive glioblastoma (Joshkon et al. Acta Neuropathol Commun, 2022).
Read full original descriptionShow less
Now, the investigators objective is to prospectively monitor the soluble CD146 value in plasma from patients treated by bevacizumab for recurrent glioblastoma.
The investigators will collect plasma at baseline, before the first bevacizumab administration, before the second administration, at the time of first MRI evaluation and at progression. Plasma CD146 value will be analyzed by ELISA.
The investigators expect to confirm the correlation between soluble CD146 value in plasma and patient response to bevacizumab.
The group in the trial
- plasma collectionOther group
Plasma samples will be prospectively collected at relevant time points during patient treatment.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Predictive Value of Soluble CD146 in Patients With Recurrent Glioblastoma Treated by Bevacizumab
- Plain-language title
- Tests a blood marker to predict response to bevacizumab in recurrent glioblastomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 2 February 2024